stockrowBioNTech SE Sponsored ADR
BNTX Healthcare Biotechnology
BioNTech SE Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 9.07% from fiscal 2024.
- Revenue
- −16.4%
- EPS
- +708.4%
- Free cash flow
- −123.8%
- Total debt
- +44.4%
Quarter to September 2026, against a year earlier
Follow BNTX
Alert me
BioNTech SE Sponsored ADR (BNTX) Current ratio
BioNTech SE Sponsored ADR's current ratio at the end of the quarter to 30 September 2026 was 8.6×, up 1.0× from fiscal 2025 (7.5×). Over the past ten years it has ranged from 1.2× (fiscal 2017) to 9.4× (fiscal 2023); the current reading is higher than 89% of that period. That is above the Biotechnology industry median of 4.9× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 7.5× | 1.14% |
| FY2024 | 7.5× | (20.98%) |
| FY2023 | 9.4× | 26.94% |
| FY2022 | 7.4× | 71.62% |
| FY2021 | 4.3× | 57.39% |
| FY2020 | 2.8× | (32.17%) |
| FY2019 | 4.1× | 13.91% |
| FY2018 | 3.6× | 200.61% |
| FY2017 | 1.2× | — |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 8.6× | 8.97% |
| Jun 2026 | 7.8× | (10.82%) |
| Mar 2026 | 8.8× | 16.76% |
| Dec 2025 | 7.5× | 5.81% |
| 26 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| ROIV Roivant Sciences Ltd. compare | 16.7× |
| BNTX BioNTech SE Sponsored ADR | 8.6× |
| INCY Incyte Corporation compare | 3.8× |
| EXEL Exelixis, Inc. compare | 3.2× |
| ASND Ascendis Pharma A/S compare | 3.0× |
| INSM Insmed, Inc. compare | 2.9× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 2.5× |
| GMAB Genmab A/S Sponsored ADR compare | 2.5× |
| BBIO BridgeBio Pharma, Inc. compare | 2.1× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on BNTX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Beneish M-score
- The full statement